Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • InderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Bolag under bevakning
    • Teamet

Du verkar använda en bredare skärm. Vill du aktivera en bredare visningsupplevelse på denna sida?

Pharma Equity Group - Market Update & Q&A

Av HC Andersen Capital
Pharma Equity Group

Meet and ask questions to CEO Thomas K. Selsø from Pharma Equity Group on Monday, December 11th, 2023 at 2 PM. CEO Thomas K. Selsø will provide an update on what has happened in 2023 and outline focus areas for 2024 which will be followed by a Q&A session. No question is too big or too small, everyone should have the opportunity to ask questions.

Pharma Equity Group focuses on repositioning existing APIs (Active Pharmaceutical Ingredients) for other indications. Pharma Equity Group acquired a larger portfolio of phase 2 projects through the purchase of Reponex, within major disease areas. These include bacterial peritonitis, chronic skin wounds, inflammatory bowel diseases, as well as colon and rectal cancer. The company operates with a partnership structure for all its phase 3 projects.

Disclaimer: HC Andersen Capital receives payment from Pharma Equity Group for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 20.11.2023, 2.45 PM.

Recent videos

Talenom - Planned demerger and strategies of Talenom and Easor
2025-12-18 11:00 Talenom
Conference call with Fabege´s new CEO Bent Oustad
2025-12-18 10:00 Fabege
Investing in the life science sector
2025-12-18 07:47
Life Science Companies as Investments | Life Science Night Dec. 9, 2025
2025-12-16 08:30 Aiforia Technologies
Truecaller, Webcast, Press Conference, 2025
2025-12-15 13:00 Truecaller
Titta på alla videos
Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.